Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division
By I. Edwards HealthDay Reporter
WEDNESDAY, May 7, 2025 — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.
The division oversees vaccines and biologic medicines, including gene therapies, CNN reported.
Prasad is a hematologist-oncologist, a specialist in treating cancers of the blood. He has been a vocal critic of the U.S. government's response to the COVID-19 pandemic. He has questioned school closures, mask mandates and COVID booster shots.
He takes over from Dr. Peter Marks, who led the division for 13 years and played a major role in the COVID vaccine rollout. Marks resigned in March, writing in a letter that U.S. health secretary Robert F. Kennedy Jr. did not value science and transparency.
FDA Commissioner Dr. Marty Makary praised Prasad’s background, saying he has a "long and distinguished history in medicine" and highlighted his oncology research, according to CNN.
Prasad’s appointment comes as the FDA plans to require future vaccines to be tested through placebo-controlled trials.
Public health officials are also reconsidering recommendations for COVID vaccines for children — recommendations Prasad has questioned, because kids face lower risks from the virus than older people and those with weakened immune systems.
Amid news of his appointment, biotech stocks fell more than 5%. Sarepta Therapeutics, which makes a gene therapy for Duchenne muscular dystrophy, saw its stock drop nearly 25%.
Prasad had criticized the FDA’s approval of that treatment, Elevidys, saying its benefits were uncertain.
In a social media post earlier this year, Prasad wrote, “The FDA did nothing to speed gene therapy, other than talk about how they will use uncontrolled endpoints. But we want to speed effective gene therapy, not ineffective gene therapy. The FDA had no solution for that.”
Sources
- CNN, May 6, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Depressive Symptoms Increased for U.S. Adults During Pandemic
WEDNESDAY, May 7, 2025 -- The prevalence of depressive symptoms increased among U.S. adults during the pandemic, according to a research letter published online May 5 in JAMA...
Top FDA Inspection Official to Retire Amid Staff Frustration
WEDNESDAY, May 7, 2025 — The official in charge of federal food and drug safety inspections will retire May 14. Michael Rogers, associate commissioner for inspections and...
Europe Launches $565 Million Campaign to Attract U.S. Scientists
WEDNESDAY, May 7, 2025 — The European Union is looking to capitalize on the Trump administration's dismantling of U.S. research programs to beef up its own. A $565 million...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.